U.S. Markets closed

Biofrontera to Participate in Two Upcoming Investor Conferences

Leverkusen, Germany, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its participation in two upcoming conferences.

Prof. Dr. Hermann Lübbert, Biofrontera’s Chief Executive Officer, and Thomas Schaffer, Chief Financial Officer, are scheduled to participate at the Benchmark Microcap Discovery Conference being held on November 29, 2018 at the Palmer House Hilton in Chicago, IL.

Mr. Schaffer will also present at the 11th Annual LD Micro Main Event being held on December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Event: Benchmark Microcap Discovery Conference
Format: 1x1 Meetings
Date: Thursday, November 29, 2018

Location: Palmer House Hilton, Chicago, IL
Event: 11th Annual LD Micro Main Event
Format: Presentation & 1x1 Meetings
Date: Tuesday, December 4, 2018
Time: 9:30 am PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 4

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer             

+49 (0) 214 87 63 2 0

ir@biofrontera.com

IR UK: Seton Services

Toni Vallen             

+44 (0) 207 224 8468

IR and PR US: The Ruth Group

IR: Tram Bui

PR: Kirsten Thomas               

+1 646-536-7035

+1 508-280-6592